Foghorn Therapeutics (FHTX) Income from Continuing Operations: 2020-2025
Historic Income from Continuing Operations for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$16.5 million.
- Foghorn Therapeutics' Income from Continuing Operations rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 17.80%. This contributed to the annual value of -$86.6 million for FY2024, which is 11.99% up from last year.
- Latest data reveals that Foghorn Therapeutics reported Income from Continuing Operations of -$16.5 million as of Q3 2025, which was up 12.34% from -$18.8 million recorded in Q2 2025.
- Over the past 5 years, Foghorn Therapeutics' Income from Continuing Operations peaked at -$14.3 million during Q3 2023, and registered a low of -$30.5 million during Q1 2023.
- Its 3-year average for Income from Continuing Operations is -$21.9 million, with a median of -$20.2 million in 2025.
- As far as peak fluctuations go, Foghorn Therapeutics' Income from Continuing Operations plummeted by 68.90% in 2021, and later soared by 44.33% in 2023.
- Quarterly analysis of 5 years shows Foghorn Therapeutics' Income from Continuing Operations stood at -$28.5 million in 2021, then fell by 1.33% to -$28.9 million in 2022, then grew by 16.55% to -$24.1 million in 2023, then rose by 19.09% to -$19.5 million in 2024, then grew by 13.87% to -$16.5 million in 2025.
- Its Income from Continuing Operations was -$16.5 million in Q3 2025, compared to -$18.8 million in Q2 2025 and -$20.2 million in Q1 2025.